CIK 0001606498
AVNS AVANOS MEDICAL, INC.
Insider trading from SEC Form 4. Last filing Jul 28, 2026.
In brief
AVANOS MEDICAL, INC. (AVNS) has 58 SEC Form 4 filings on file from 10 insiders, the latest filed on Jul 28, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at AVNS. The newest: Kerr Holbrook (SVP, Chief Commercial Officer) sold $165k of stock on Nov 18, 2025, filed Nov 19, 2025, scored 31 (weak). The largest of the 3 shown: Gary Blackford (director) bought $659k on Aug 13, 2025, scored 45 (moderate).
2 Form 144 notices of planned sales are on file, the latest filed Nov 18, 2025.
Last 90 days
Signals
Open-market buys and sells at AVANOS MEDICAL, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Kerr Holbrook SVP, Chief Commercial Officer sell | $165k 15,000 shares | -15% | - | |
| 45Moderate | Gary Blackford director buy | $659k 60,000 shares | +84% | - | |
| 25Weak | Kerr Holbrook SVP, Chief Commercial Officer sell | $107k 7,000 shares | -8% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 18, 2025 | Holbrook Kerr Former Officer | 15,000 0.03% of outstanding | $165k | Nov 18, 2025 | none |
| Mar 6, 2025 | Holbrook Kerr Officer | 7,000 0.02% of outstanding | $107k | Mar 6, 2025 | none |
Transactions
The newest 50 of 115 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Indrani Lall Franchini director | DDisposition to issuer Common Stock | -4,817 | $25.00 | $120k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Julie Ann Shimer director | DDisposition to issuer Common Stock | -50,090 | $25.00 | $1.3M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Gary Blackford director | DDisposition to issuer Common Stockindirect: Shares held in trust. | -40,000 | $25.00 | $1.0M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | David Pacitti Chief Executive Officer | DDisposition to issuer Common Stock | -322,194 | $25.00 | $8.1M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Lisa Egbuonu-Davis director | DDisposition to issuer Common Stock | -13,811 | $25.00 | $345k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | DDisposition to issuer Common Stock | -135,596 | $25.00 | $3.4M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Patrick J Oleary director | DDisposition to issuer Common Stock | -54,640 | $25.00 | $1.4M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Sigfrido Delgado SVP, Operations | DDisposition to issuer Common Stock | -55,741 | $25.00 | $1.4M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | AGrant or award Common Stock | +96,121 | $0.00 | $0 | 96,121 | Jul 28, 2026 |
| Jul 27, 2026 | Gary Blackford director | DDisposition to issuer Common Stock | -79,590 | $25.00 | $2.0M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Patrick J Oleary director | DDisposition to issuer Restricted Share Unitsderivative | -12,003 | $25.00 | $300k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Lisa Egbuonu-Davis director | DDisposition to issuer Restricted Share Unitsderivative | -12,003 | $25.00 | $300k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Julie Ann Shimer director | DDisposition to issuer Restricted Share Unitsderivative | -12,003 | $25.00 | $300k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | David Pacitti Chief Executive Officer | AGrant or award Common Stock | +444,730 | $0.00 | $0 | 444,730 | Jul 28, 2026 |
| Jul 27, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Common Stock | +54,886 | $0.00 | $0 | 54,886 | Jul 28, 2026 |
| Jul 27, 2026 | Indrani Lall Franchini director | DDisposition to issuer Restricted Share Unitsderivative | -12,003 | $25.00 | $300k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | DDisposition to issuer Common Stock | -96,121 | $25.00 | $2.4M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Gary Blackford director | DDisposition to issuer Restricted Share Unitsderivative | -12,003 | $25.00 | $300k | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Sigfrido Delgado SVP, Operations | DDisposition to issuer Common Stock | -54,886 | $25.00 | $1.4M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | David Pacitti Chief Executive Officer | DDisposition to issuer Common Stock | -444,730 | $25.00 | $11M | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -69,630 | - | - | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Sigfrido Delgado SVP, Operations | DDisposition to issuer Employee Stock Option (right to buy)derivative | -37,520 | - | - | 0 | Jul 28, 2026 |
| Jul 27, 2026 | David Pacitti Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -239,354 | - | - | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Sigfrido Delgado SVP, Operations | DDisposition to issuer Employee Stock Option (right to buy)derivative | -21,914 | - | - | 0 | Jul 28, 2026 |
| Jul 27, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -21,038 | - | - | 0 | Jul 28, 2026 |
| May 8, 2026 | Julie Ann Shimer director | AGrant or award Restricted Share Unitsderivative | +12,003 | $0.00 | $0 | 12,003 | May 12, 2026 |
| May 8, 2026 | Patrick J Oleary director | AGrant or award Restricted Share Unitsderivative | +12,003 | $0.00 | $0 | 12,003 | May 12, 2026 |
| May 8, 2026 | Indrani Lall Franchini director | AGrant or award Restricted Share Unitsderivative | +12,003 | $0.00 | $0 | 12,003 | May 12, 2026 |
| May 8, 2026 | Lisa Egbuonu-Davis director | AGrant or award Restricted Share Unitsderivative | +12,003 | $0.00 | $0 | 12,003 | May 12, 2026 |
| May 8, 2026 | Gary Blackford director | AGrant or award Restricted Share Unitsderivative | +12,003 | $0.00 | $0 | 12,003 | May 12, 2026 |
| Apr 22, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | FTax withholding Common Stock | -4,228 | $24.64 | $104k | 135,596 | Apr 24, 2026 |
| Apr 22, 2026 | Sigfrido Delgado SVP, Operations | FTax withholding Common Stock | -4,264 | $24.64 | $105k | 55,741 | Apr 24, 2026 |
| Apr 14, 2026 | David Pacitti Chief Executive Officer | FTax withholding Common Stock | -21,194 | $14.53 | $308k | 322,194 | Apr 16, 2026 |
| Mar 13, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Common Stock | +15,886 | $0.00 | $0 | 60,005 | Apr 1, 2026 |
| Mar 13, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | AGrant or award Common Stock | +29,481 | $0.00 | $0 | 139,824 | Apr 1, 2026 |
| Mar 13, 2026 | David Pacitti Chief Executive Officer | AGrant or award Common Stock | +101,341 | $0.00 | $0 | 343,388 | Apr 1, 2026 |
| Mar 13, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Common Stock | +15,886 | $0.00 | $0 | 60,005 | Apr 1, 2026 |
| Mar 13, 2026 | David Pacitti Chief Executive Officer | AGrant or award Common Stock | +101,341 | $0.00 | $0 | 343,388 | Apr 1, 2026 |
| Mar 13, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | AGrant or award Common Stock | +29,481 | $0.00 | $0 | 139,824 | Apr 1, 2026 |
| Mar 13, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +70,115 | $0.00 | $0 | 96,697 | Apr 1, 2026 |
| Mar 13, 2026 | David Pacitti Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +241,021 | $0.00 | $0 | 241,021 | Apr 1, 2026 |
| Mar 13, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Employee Stock Option (right to buy)derivative | +37,782 | $0.00 | $0 | 59,696 | Apr 1, 2026 |
| Mar 13, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Employee Stock Option (right to buy)derivative | +37,520 | $0.00 | $0 | 59,434 | Apr 1, 2026 |
| Mar 13, 2026 | David Pacitti Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +239,354 | $0.00 | $0 | 239,354 | Apr 1, 2026 |
| Mar 13, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +69,630 | $0.00 | $0 | 96,212 | Apr 1, 2026 |
| Mar 13, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Common Stock | +15,886 | $0.00 | $0 | 60,005 | Mar 17, 2026 |
| Mar 13, 2026 | David Pacitti Chief Executive Officer | AGrant or award Common Stock | +101,341 | $0.00 | $0 | 343,388 | Mar 17, 2026 |
| Mar 13, 2026 | Scott Michael Galovan SVP, Chief Financial Officer | AGrant or award Common Stock | +29,481 | $0.00 | $0 | 139,824 | Mar 17, 2026 |
| Mar 13, 2026 | John Joseph Hurley Principal Accounting Officer | AGrant or award Common Stock | +2,211 | $0.00 | $0 | 13,592 | Mar 17, 2026 |
| Mar 13, 2026 | Sigfrido Delgado SVP, Operations | AGrant or award Employee Stock Option (right to buy)derivative | +37,520 | $0.00 | $0 | 59,434 | Mar 17, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Gary Blackforddirector
- Sigfrido DelgadoSVP, Operations
- Lisa Egbuonu-Davisdirector
- Indrani Lall Franchinidirector
- Scott Michael GalovanSVP, Chief Financial Officer
- Kerr HolbrookSVP, Chief Commercial Officer
- John Joseph HurleyPrincipal Accounting Officer
- Patrick J Olearydirector
- David PacittiChief Executive Officer
- Julie Ann Shimerdirector
Questions about AVNS
Answered from the filings on this page, as of the latest one.
Are insiders buying AVNS?
No. In the last 90 days no insider at AVANOS MEDICAL, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AVNS on the open market?
Kerr Holbrook (SVP, Chief Commercial Officer) sold $165k of AVNS on Nov 18, 2025 and filed the Form 4 on Nov 19, 2025. InsiderTell scored 31 (weak).
How many insiders file Form 4 at AVANOS MEDICAL, INC.?
10 people have filed a Form 4 at AVANOS MEDICAL, INC., among them Gary Blackford (director), Sigfrido Delgado (SVP, Operations), Lisa Egbuonu-Davis (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.